- Details
- Oliver Sartor speaks with Øyvind Bruland about his work in radiopharmaceuticals, from the development of radium-223 to his current work with Oncoinvent. Dr. Bruland shares his journey from traditional oncology to radiopharmaceuticals, explaining his attraction to alpha particles for treating chemotherapy-resistant disease. He discusses Oncoinvent's promising work with radium-224 microparticles for...
|
- Details
- Oliver Sartor talks with Volker Wagner about the Orano Med’s work with radiopharmaceuticals, particularly lead-212. Dr. Wagner explains why radiopharmaceuticals represent an important treatment modality in cancer care, highlighting their ability to deliver radiation systemically and trigger immunogenic cell death. He emphasizes Orano Med's unique position in the lead-212 space, thanks to their acc...
|
- Details
- Oliver Sartor interviews Jeff Humphrey about radiopharmaceuticals in cancer treatment. Dr. Humphrey discusses Lantheus' work with various isotopes, including lutetium, lead-212, and astatine-211, highlighting their potential advantages in targeted therapy. He emphasizes the company's interest in the gastrin-releasing peptide receptor (GRPR) as a complementary target to PSMA in prostate cancer. Dr....
|
- Details
- Oliver Sartor interviews Martin Pomper about radiopharmaceuticals and theranostics in cancer treatment. Dr. Pomper discusses his long-standing interest in the field, highlighting the advantages of small molecule radiopharmaceuticals over antibodies and other biological agents. He explains his focus on Astatine-211 as a promising alpha emitter for targeted therapy, citing its single alpha decay and...
|
- Details
- Oliver Sartor interviews Chris Behrenbruch about radiopharmaceuticals in cancer treatment. Dr. Behrenbruch discusses his passion for nuclear medicine, emphasizing its multidisciplinary nature and potential for patient impact. They explore the complexities of isotope selection, particularly Lutetium-177 and Actinium-225, highlighting the importance of matching isotopes to specific biological proble...
|
- Details
- Oliver Sartor interviews Jessica Jensen about radiopharmaceuticals in cancer treatment. Ms. Jensen discusses her passion for the field, emphasizing the patient-centric approach and the immediate insights gained from molecular imaging. They explore the complexities of isotope selection, highlighting the importance of understanding tumor heterogeneity and target expression. Ms. Jensen stresses the n...
|
- Details
- Oliver Sartor interviews Chuck Conroy about Nucleus RadioPharma’s role in radiopharmaceutical manufacturing and distribution. Mr. Conroy explains that Nucleus RadioPharma aims to support both small and large pharmaceutical companies in developing and delivering radioligand therapies. The company is building extensive manufacturing facilities across the US, with plans to create more capacity than c...
|
- Details
- Sergio Calvo discusses GE's role in theranostics, emphasizing their broad portfolio spanning cyclotrons, radiosynthesis modules, and imaging devices. He highlights GE's recent acquisition of MIM Software to enhance flexibility in image analysis for diverse radioligand therapies. Mr. Calvo predicts significant growth in the field, expecting a twentyfold increase in patient treatments within a decad...
|
- Details
- Oliver Sartor interviews John Valliant about the potential of radiopharmaceuticals in cancer treatment. Dr. Valliant discusses the advantages of targeted radiation therapy, particularly using Actinium-225, highlighting its efficacy and potential for combination therapies. He emphasizes the unique ability of radiopharmaceuticals to combine imaging and treatment, allowing for better patient selectio...
|
- Details
- Oliver Sartor interviews Anna Karmann about the potential of radiopharmaceuticals in cancer treatment. Dr. Karmann discusses the advantages of Lead-212, highlighting its alpha-emitting properties, short half-life, and potential for frequent dosing strategies. She emphasizes the unique benefits of Lead-212, including its synergy with the immune system and logistical advantages in drug delivery. Dr....
|
